
Please try another search
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
John Dawson | - | 2008 | Executive Director & Advisor |
Frederic Roch Doliveux | 68 | 2020 | Non-Executive Chair |
Frank Mathias | 62 | 2023 | CEO & Director |
Lucinda Crabtree | 45 | 2024 | CFO & Director |
Dame Kay Davies | 74 | 2021 | Chair of Innovation & Technology Excellence Board and Senior Independent Director |
Heather Preston | 59 | 2018 | Member of Innovation & Technology Excellence Board and Independent Director |
Peter L. Stern | - | - | Member of Scientific Advisory Board |
Krystof Bankiewicz | - | - | Member of Scientific Advisory Board |
William Langston | - | - | Member of Scientific Advisory Board |
Robert Ghenchev | 42 | 2019 | Non-Executive Director |
Bruce L. Levine | - | 2025 | Member of Innovation & Technology Excellence Board |
Colin Michael Bond | 65 | 2025 | Independent Non-Executive Director |
Peter Georg Soelkner | 59 | 2024 | Independent Vice Chair |
Namrata P. Patel | 59 | 2022 | Independent Non-Executive Director |
Luk H. Vandenberghe | 48 | 2025 | Member of Innovation & Technology Excellence Board |
Uwe Buecheler | - | 2025 | Member of Innovation & Technology Excellence Board |
Axel Schambach | - | 2025 | Member of Innovation & Technology Excellence Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review